Bionik Laboratories Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Bionik Laboratories Corp 주요 수익원은 Therapeutics for Hematological, Pulmonary and Cardiovascular Disorders이며, 최신 수익 발표에서 수익은 3,550,000입니다. 지역별로는 United States이 Bionik Laboratories Corp의 주요 시장이며, 수익은 3,550,000입니다.
Bionik Laboratories Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 Bionik Laboratories Corp의 순손실은 $-4입니다.
Bionik Laboratories Corp에 부채가 있나요?
예, Bionik Laboratories Corp의 부채는 5입니다.
Bionik Laboratories Corp의 발행 주식은 몇 주인가요?
Bionik Laboratories Corp의 총 발행 주식은 6.87주입니다.
주요 통계
이전 종가
$0.0001
시가
$0.0001
일일 범위
$0.0001 - $0.0001
52주 범위
$0.0001 - $0.0001
거래량
578
평균 거래량
0
배당수익률
--
EPS(TTM)
-0.72
시가총액
$1.2K
BNKL란 무엇인가요?
Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. The company is headquartered in Watertown, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2012-06-12. Its product portfolio includes three InMotion Robots for rehabilitation following stroke and other neurological conditions and four products in varying stages of development. The InMotion robots offer patient-adaptive therapy, intended to restore upper-extremity motor control for a range of neurological conditions and recovery stages, including early recovery from acute stroke. InMotion Robots also provide objective evaluation assessments intended to measure and report the patient’s level of motor impairment and progress during therapy. Its solutions include InMotion Therapy, InMotion ARM, InMotion ARM/HAND, InMotion EVAL, InMotion Connect, InMotion for Physical Therapy, and InMotion for Occupational Therapy. InMotion Robotics provides the occupational therapist with a range of useful protocols designed to reduce many types of upper extremity neurological impairments.